Background: A study conducted in 1983 to identify and rank the symptoms experienced by patients receiving cancer chemotherapy reported that vomiting and nausea were the most important symptoms experienced. With the advent of new antiemetic regimens and changes in cancer chemotherapy, it was anticipated that changes may have occurred in patient perception of symptoms. The study was therefore repeated in 1993.
Decisions about cancer chemotherapy involve weighing up the likely benefits and side effects of the treatment. Traditionally this decision has been made in a paternalistic fashion by the doctor. During the last decade, the centrality of the patients' point of view in setting priorities for treatment and evaluating medical outcomes has been recognised [1, 2] . Patients increasingly want to be involved in decisions about their care and doctors want to incorporate patient needs and priorities into their treatment recommendations [3, 4] . For this to be possible, doctors need to provide patients with relevant information about the issues which are important to them. Feedback about the likely impact of treatment, especially if it is based on patient-generated data, would be a valuable component of this information.
The majority of research into the side effects of chemotherapy has focused on the influence that nausea and vomiting have on patients' quality of life (e.g., [5] [6] [7] ). In 1983 we conducted a study to identify and rank both the physical and psychosocial symptoms experienced while receiving cancer chemotherapy [8] .
In that study, a profile of the relative importance of the symptoms was compiled. Vomiting was the most important symptom identified by patients.
In the past ten years new antiemetic regimens have been developed and there have also been changes in cancer chemotherapy and supportive care [9] . We anticipated that patient perceptions of the side effects of chemotherapy might have changed and that a smaller proportion of patients would report nausea and vomiting as major side effects. We therefore repeated the study in 1993 using the same measures. The aims of the current study were (i) to identify the main symptoms experienced while receiving cancer chemotherapy in 1993, (ii) to describe the changes that may have occurred since the previous study and (iii) to identify priorities for research into ways of helping patients cope with current chemotherapy regimens.
Patients and methods
One hundred and fifty-five cancer patients receiving outpatient or inpatient chemotherapy at a large urban teaching hospital participated in the study. Inclusion criteria were ability to read English and having completed at least one cycle of chemotherapy. Demographic and disease characteristics of the patients are shown in Table 1 . All patients had received chemotherapy within the four-week period prior to study entry. Chemotherapy regimens were grouped as those containing cisplatin (25 patients), those containing doxorubicin but not cisplatin (27 patients), those containing cyclophosphamide, methotrexate and fluorouracil (CMF 47 patients) and other sys- temic chemotherapy (56 patients), for comparability with the previous study. All but 28 patients received antiemetic drugs. Patient characteristics were similar to those in the 1983 study, except that patients receiving adjuvant therapy were included (whereas the previous study involved only patients with advanced disease). The majority of adjuvant patients received CMF (62%). Only patients with advanced disease were included in comparisons between the 1983 and 1993 studies. There were more females (76% versus 61%) and fewer patients received doxorubicin than in the previous study (18% versus 33%). As this study was in essence a duplication of the 1983 study, the methodology used in 1983, despite some limitations, was retained. Two sets of white cards were prepared. The interview procedure was as described previously [8] . On each card was the name of one potential side effect of chemotherapy. Group A (45 cards) listed physical symptoms and Group B (28 cards) psychosocia] symptoms (Tables 2 and 3 ). Group A cards were presented first, one at a time. The patients were asked by an interviewer, who was blind to their diagnosis and treatment, to select all cards which described a symptom they attributed to their current chemotherapy. They were then asked to select the 5 'most troublesome' of these symptoms. This procedure was repeated for Group B cards. The five cards selected from each group were combined and the patient was asked to select from these ten cards, the five most severe symptoms and rank them from most to least severe.
An overall ranking of the severity of symptoms was obtained. Five points were allocated to symptoms ranked as the most severe, decreasing to one point for symptoms ranked as least severe. The points allocated to each symptom were added and divided by the number of patients in the sample to give an overall score. These scores were then ranked, to indicate the 10 symptoms regarded by patients as most severe.
Patients were also asked to retrospectively complete a series of linear analogue self assessment (LASA) scales documenting the severity of nausea and vomiting before, within 24 hours of chemotherapy and beyond 24 hours of chemotherapy, using standard LASA methodology [10] . Patients also answered a number of other questions about their general physical state, and their opinion of the purpose and efficacy of treatment The treating doctor's opinion of the intent of treatment was recorded.
Results

Symptoms experienced
Patients reported experiencing an average of 20 symptoms, 13 of which were physical and 7 psychosocial. Over 50% of patients reported experiencing nausea, tiredness, hair loss, concern about effects on family, depression, anxiety and dread of treatment, while 40%-50% of patients reported experiencing vomiting, difficulty sleeping, loss of taste, loss of appetite, passing more urine, sore mouth, dry skin and effects on their social lives. Other symptoms were experienced less frequently, but 39 of the 73 symptoms were reported by more than 25% of all patients interviewed. (Tables 2  and 3) .
Logistic regression techniques were used to analyse the relationship between symptoms and treatment groups (cisplatin, doxorubicin or CMF), and demographic groupings (Table 4) . Because of the large number of symptoms examined, the analyses used the demographic or treatment variable as the outcome and the symptoms as explanatory variables. This methodology and the fact that there was irretrievable confounding between some of the variables (for example, all breast cancer patients were female and CMF was used only for breast cancer) meant that the analysis of symptoms could not be controlled for type of cancer, age and gender. This imposes some limitations on the interpretation of the results, which are highlighted in the Discussion.
Several differences observed were as expected, for example a greater percentage of patients receiving cisplatin reported experiencing deafness (P < 0.01) while more patients receiving doxorubicin reported coloured urine. More surprising were the findings that equal numbers of patients receiving cisplatin and doxorubicin reported pins and needles (whereas one would expect this symptom only in those receiving cisplatin), and that more patients receiving cisplatin reported negative effects on family and friends (P < 0.05).
More females reported apprehension about treatment (P < 0.001), while men were more likely to notice practical difficulties such as transport and parking. Not surprisingly, younger patients reported more concern about sexuality and body image.
Most severe symptoms
We next examined the five symptoms patients ranked as the most severe. Nausea was reported as the most severe symptom, with 50% of patients ranking it within the five most severe and 12% reporting it as the most severe. Tiredness was ranked by 35% of patients among the five most severe and by 10% as the most severe, while 33% of patients reported loss of hair among the top five and 12% as the most severe. Also included within the top ten symptoms selected as the most severe were effect on family, vomiting, depression, dread of treatment, difficulty sleeping, feeling anxious/ tense and having to have a needle (descending rank). Logistic regressions were conducted to determine if any of the symptoms felt by patients to be most severe 1 were predictive of treatment received and demographics (see Table 5 ). As ranking within the five most severe symptoms was highly variable between patients (as shown by Kendall's W), we restricted the analysis to comparing whether each symptom was included or not included in the five most severe. There were no significant differences in the physical symptoms regarded as the most severe, according to drug regimen. However, several psychosocial concerns differentiated between groups; for example a greater percentage of patients receiving cisplatin versus doxorubicin and CMF placed concern for the family (P< 0.001) and anxiety about infertility (P < 0.01) within the five most severe symptoms, while patients receiving CMF were more likely to report fear of needles (P < 0.01), a feeling that they did not want treatment (P < 0.05), worry about damage caused by the treatment (P < 0.05) and hair loss (P < 0.05). Four symptoms were regarded as most severe by a larger percentage of males than females: aches and pains (P<0.01) abdominal pain (P<0.05), loss of sexual ability (P < 0.05) and difficulty concentrating (P<0.05), while more females than males regarded fear of needles as a severe symptom (P < 0.05). A small number of older patients placed physical symptoms such as dyspnoea (P< 0.001), pins and needles and tinnitus (both P < 0.01) within the five most severe symptoms, while no younger patient did. Not surprisingly, younger patients were more likely than older patients to regard anxiety about infertility as a severe symptom (P < 0.001).
Nausea and vomiting pre, within and post 24 hours of chemotherapy
All patients retrospectively completed several linear analogue self assessment (LASA) scales documenting the severity of anticipatory nausea and vomiting, and nausea and vomiting within and more than 24 hours after chemotherapy. Scores ranged from 0 (no discomfort) to 100 (extreme discomfort). A score of >75 was interpreted as indicating a significant level of discomfort. On this basis, 17% of patients reported anticipatory nausea and 5% anticipatory vomiting while 51% of patients reported nausea within 24 hours and 57% beyond 24 hours of chemotherapy. Twenty-four percent of patients reported vomiting within 24 hours and 29% beyond 24 hours of chemotherapy. Logistic regressions were carried out to explore the relative power of the LASA scores in predicting whether nausea and vomiting were selected as one of the top five symptoms. Delayed vomiting (24 hours or more after chemotherapy) was the most powerful predictor of the ranking of vomiting (P < 0.001), followed by vomiting and nausea within 24 hours of chemotherapy. Nausea within 24 hours of chemotherapy was the strongest predictor of the nausea ranking (P < 0.001), followed by delayed nausea (after 24 hours) and vomiting within 24 hours after chemotherapy. Anticipatory nausea and vomiting did not affect how patients ranked nausea and vomiting.
The relationships between treatment type and LASA ratings were explored using analyses of variance. Anticipatory nausea and vomiting were not related to treatment regimen, but as expected, patients receiving cisplatin reported significantly worse nausea and vomiting within and beyond 24 hours of chemotherapy, than patients on doxorubicin or other chemotherapies (see Table 6 ).
Changes since 1983
As the previous study included only 99 patients with advanced cancer, we restricted the analysis of changes in the present group to the same criteria to enable a direct comparison. Some raw data were not available from the 1983 study and it was not possible to perform statistical comparisons of the two groups, therefore our discussion is limited to descriptive comments. The changes in scores from 1983 to 1993 of the 10 symptoms rated as most severe in 1983, are shown in Figure 1 . Vomiting showed the most dramatic change, from a mean rank of 1 in 1983 to 5 in 1993. This was consistent for all subgroups but was particularly evident for the older age group (>60) who ranked vomiting 15th.
The overall ranking for 'thought of having treatment' dropped from 4 to 12, although patients with ovarian cancer still report this as the fourth most severe symptom. The length of time treatment takes decreased substantially in order of ranking from 5 to 21, and this was reflected across all subgroups. Fear of a needle was less problematic in 1993 (ranked 6th in 1983 versus 12th in 1993).
On the other hand, some symptoms appeared to be worse in 1993. Tiredness was rated as more severe in 1993 (ranked 8th in 1983 versus 2nd in 1993), and Table 6 . Mean LASA ratings (0-100) of pre, concurrent and post nausea and vomiting by treatment concern about the effect on friends and family members increased (ranked 10th in 1983 and 3rd in 1993). Difficulty in sleeping also rated worse (ranked 9th in 1983 and 6th in 1993).
Conclusions
Cancer patients receiving chemotherapy in 1993 experienced many symptoms. Although some of these symptoms may be due to the disease rather than the treatment, they nonetheless suggest a significant level of treatment-related morbidity in these patients. In this sample of 155 cancer patients, an average of 20 symptoms were attributed to their chemotherapy, 13 of which were physical and 7 psychosocial. This is considerably more than reported by Tierney et al. [11] , who found that patients reported in interview an average of 5.4 symptoms. This difference is probably due to the prompts provided in our study, versus the open invitation to list symptoms provided by Tierney et al. However, even those symptoms scoring as the most severe were not a problem for all patients. For example, nausea was the most common symptom reported, experienced by 73% of patients, but was selected as the most severe by only half of the sample. Of the total 73 symptoms from which patients were asked to select, only eight were experienced by more than 50% of patients (three physical and five psychosocial).
Our results also identified several changes from the 1983 study which suggest a reduction in the severity of some of the side effects of chemotherapy. The overall rankings for 'thought of having treatment', 'length of treatment' and 'having a needle' have substantially decreased from 1983 to 1993, suggesting that the entire experience of chemotherapy is less dreaded by patients today.
In terms of relative severity, nausea was clearly the most troublesome symptom, followed by tiredness and hair loss. Vomiting, which was the most severe symptom reported in 1983, was ranked 5th by this group of patients in 1993. Nausea and vomiting are the most widely recognised side effects of chemotherapy, and considerable effort has been expended in the last ten years to reduce their impact. In comparison to 1983, high dose Metoclopramide combinations and serotonin antagonists such as ondansetron ± steroid, have led to a significantly higher rate of control of emetic episodes following chemotherapy. These advances however, have not translated into improved control of nausea, and particularly in the less well investigated area of delayed nausea. In this study, 57% of patients reported delayed nausea, a figure not dissimilar to those reported by prevalence studies [12] .
Four of the ten most severe symptoms reported were in the psychosocial domain. Concern for family and partner, effect on work and home-duties, anxiety and depression featured prominently. These side effects were reported as severe by more patients in 1993 than in 1983. This apparent increase in the psychosocial impact of cancer chemotherapy may reflect a tendency for psychosocial concern to fill a void left by a reduction in the physical symptoms. Alternatively, with patients becoming more vocal in demanding information, involvement in clinical decision-making and emotional support, they may feel more able to talk about psychosocial concerns. Another explanation is that outpatient treatment, more common in 1993, may have placed greater demands on the family/partner and added to psychological stressors.
Cooper and Georgiou [13] , in a study of 300 patients, 150 hospital specialists and 75 cancer-care nurses in France, Italy and the UK. also reported that the main impact of chemotherapy on patients' quality of life related to worry about the impact of illness and treatment on family and work, rather than day-to-day lifestyle limitations. The patient need most frequently mentioned by specialists and nurses in this study was for psychologist back-up. These findings suggest that interventions designed to identify and address these issues would be welcomed by patients.
We explored differences in the perception of symptoms according to chemotherapy regime, age and sex. There was considerable variability between groups, emphasising the need for a sensitive and individualised approach to discussing the impact of chemotherapy with patients. For example, more patients on cisplatin (who were all inpatients and relatively young) were concerned about possible effects of the illness and treatment on family and friends. More patients on CMF did not want treatment, and were concerned that the treatment would cause damage to their bodies. These patients were mostly receiving adjuvant therapy, where the benefits of treatment are less immediate. Older patients were troubled by a range of symptoms, such as tinnitus, which did not trouble younger patients at all, while infertility (not surprisingly) was a much more significant issue for younger patients. There were also some gender specific concerns, such as loss of sexual ability among males and fear of needles among females.
There were several limitations to the current study. Most notable was the emphasis on relative, rather than absolute severity of symptoms. In addition, the physical symptoms were invariably presented first, leading to a possible order effect where patients may have became more tired and less motivated to report psychosocial concerns. The effects of type of cancer, age and gender were not controlled for in the separate analyses of symptoms, which means that some of the differences observed may be attributable to factors other than that explored. Nevertheless, this study provides important information about the variable and changing perceptions of symptoms experienced while receiving chemotherapy. Continued assessment of die adverse as well as the beneficial effects of chemotherapy is required if we are to provide maximal efficacy at the cost of least toxicity for patients with cancer.
